# reload+after+2024-01-20 08:32:20.035811
address1§2 University Plaza
address2§Suite 100
city§Hackensack
state§NJ
zip§07601
country§United States
phone§201 696 9345
website§https://www.protalix.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
fullTimeEmployees§193
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Dror  Bashan', 'age': 56, 'title': 'President, CEO & Director', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 473156, 'exercisedValue': 0, 'unexercisedValue': 15938}, {'maxAge': 1, 'name': 'Mr. Eyal  Rubin M.B.A.', 'age': 47, 'title': 'Senior VP, CFO, Treasurer & Corporate Secretary', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 813725, 'exercisedValue': 0, 'unexercisedValue': 7438}, {'maxAge': 1, 'name': 'Mr. Yaron  Naos', 'age': 59, 'title': 'Senior Vice President of Operations', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 409955, 'exercisedValue': 0, 'unexercisedValue': 7225}, {'maxAge': 1, 'name': 'Ms. Yael  Fellous', 'title': 'Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§8
compensationRisk§8
shareHolderRightsRisk§1
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.087
priceToSalesTrailing12Months§1.995075
currency§USD
dateShortInterest§1702598400
forwardEps§0.14
pegRatio§0.7
exchange§ASE
quoteType§EQUITY
shortName§Protalix BioTherapeutics, Inc. 
longName§Protalix BioTherapeutics, Inc.
firstTradeDateEpochUtc§895239000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§febb5b62-804d-3e32-9700-f4c9c8179dca
gmtOffSetMilliseconds§-18000000
targetHighPrice§16.0
targetLowPrice§10.0
targetMeanPrice§13.0
targetMedianPrice§13.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§1.151
grossMargins§0.74030995
ebitdaMargins§0.23156
trailingPegRatio§None
